256 related articles for article (PubMed ID: 34899193)
1. Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules.
Komatsu H
Front Cell Neurosci; 2021; 15():785703. PubMed ID: 34899193
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease.
Komatsu H
J Med Chem; 2021 Jan; 64(2):938-940. PubMed ID: 33443413
[TBL] [Abstract][Full Text] [Related]
3. High-throughput virtual screening of potential inhibitors of GPR52 using docking and biased sampling method for Huntington's disease therapy.
Gupta H; Sahi S
Mol Divers; 2023 Dec; ():. PubMed ID: 38038795
[TBL] [Abstract][Full Text] [Related]
4. Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease.
Tabrizi SJ; Ghosh R; Leavitt BR
Neuron; 2019 Mar; 101(5):801-819. PubMed ID: 30844400
[TBL] [Abstract][Full Text] [Related]
5. GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes.
Wang C; Zhang YF; Guo S; Zhao Q; Zeng Y; Xie Z; Xie X; Lu B; Hu Y
J Med Chem; 2021 Jan; 64(2):941-957. PubMed ID: 33185430
[TBL] [Abstract][Full Text] [Related]
6. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.
Zhang L; Wu T; Shan Y; Li G; Ni X; Chen X; Hu X; Lin L; Li Y; Guan Y; Gao J; Chen D; Zhang Y; Pei Z; Chen X
Brain; 2021 Dec; 144(11):3421-3435. PubMed ID: 34918046
[TBL] [Abstract][Full Text] [Related]
8. Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin.
Mendonça MCP; Sun Y; Cronin MF; Lindsay AJ; Cryan JF; O'Driscoll CM
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839842
[TBL] [Abstract][Full Text] [Related]
9. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
10. Latest advances on new promising molecular-based therapeutic approaches for Huntington's disease.
Cheng Y; Zhang S; Shang H
J Transl Int Med; 2024 Apr; 12(2):134-147. PubMed ID: 38779119
[TBL] [Abstract][Full Text] [Related]
11. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
12. Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.
Song H; Li H; Guo S; Pan Y; Fu Y; Zhou Z; Li Z; Wen X; Sun X; He B; Gu H; Zhao Q; Wang C; An P; Luo S; Hu Y; Xie X; Lu B
Brain; 2018 Jun; 141(6):1782-1798. PubMed ID: 29608652
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
14. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
[TBL] [Abstract][Full Text] [Related]
15. Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi-Targeted/Functional Drugs Based on Clinicaltrials.gov.
Huang C; Zheng X; Yan S; Zhang Z
Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38863261
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies for Huntington's disease.
Estevez-Fraga C; Flower MD; Tabrizi SJ
Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
[TBL] [Abstract][Full Text] [Related]
17. Huntingtin Lowering Strategies.
Marxreiter F; Stemick J; Kohl Z
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245050
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapies in Huntington's disease.
Bashir H
Expert Rev Neurother; 2019 Oct; 19(10):983-995. PubMed ID: 31181964
[No Abstract] [Full Text] [Related]
19. Drugging unconventional targets: insights from Huntington's disease.
Yu S; Liang Y; Palacino J; Difiglia M; Lu B
Trends Pharmacol Sci; 2014 Feb; 35(2):53-62. PubMed ID: 24388390
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
